Saturday 17 October 2026
Export ATXI’s income statement to Excel — free account
Avenue Therapeutics, Inc.
ATXI Healthcare Biotechnology
Avenue Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.4 million. In the quarter to June 2026, EPS fell 290.9% and free cash flow fell 169.9%, each against the same quarter a year earlier.
0.43
0.00
0.00%
Follow ATXI
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Trend | 2026e | 2027e | 2028e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price, $ | |||||||||||||||
| Price, $ | Low | — | 3,825.00 | 2,340.45 | 4,646.25 | 3,206.25 | 990.00 | 79.50 | 9.77 | 1.60 | 0.17 |
Analyst estimates 2026–2028 Powerpack |
|||
| High | — | 9,652.50 | 6,750.00 | 11,025.00 | 13,882.27 | 8,651.25 | 1,406.25 | 176.25 | 26.47 | 2.23 | |||||
| People | |||||||||||||||
| People | Employees | 3 | 2 | 6 | 4 | 4 | 4 | 2 | 3 | 2 | 1 | ||||
| Revenue/emp, $m | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.40 | |||||
| Income, $m | |||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | 1 | ||||
| Gross margin, % | — | — | — | — | — | — | — | — | — | 100.00 | |||||
| EBT | (3) | (12) | (22) | (26) | (5) | (4) | (4) | (10) | (12) | (3) | |||||
| EBT margin, % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | (209.90) | |||||
| Net income | (3) | (12) | (22) | (26) | (5) | (4) | (4) | (10) | (12) | (3) | |||||
| Depreciation | 0 | 0 | — | — | — | — | — | — | — | — | |||||
| Per share, $ | |||||||||||||||
| Per share, $ | Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.45 | ||||
| Earnings | (1,251.76) | (2,085.42) | (2,367.24) | (1,859.97) | (349.45) | (248.00) | (122.56) | (73.68) | (9.03) | (0.93) | |||||
| Cash flow | (652.80) | (1,152.88) | (2,001.76) | (1,889.14) | (315.96) | (248.34) | (261.03) | (67.03) | (6.97) | (0.59) | |||||
| Capex | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Free cash flow | (652.80) | (1,152.88) | (2,001.76) | (1,889.14) | (315.96) | (248.34) | (261.03) | (67.03) | (6.97) | (0.59) | |||||
| Book value | (3,299.20) | 3,284.75 | (69.34) | 489.21 | 161.58 | 228.54 | 112.23 | 4.64 | 1.43 | 0.59 | |||||
| Shares, m | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 3 | |||||
| Valuation, × | |||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | 0.00 | ||||
| P/S | — | — | — | — | — | — | — | — | — | 0.00 | |||||
| P/B | — | — | — | — | — | — | — | — | — | 1.16 | |||||
| EV/Sales | — | — | — | — | — | — | — | — | — | 0.00 | |||||
| EV/FCF | — | — | — | — | — | — | — | — | — | 0.18 | |||||
| Cash, $m | |||||||||||||||
| Cash, $m | Operating cash flow | (2) | (7) | (18) | (26) | (5) | (4) | (8) | (9) | (9) | (2) | ||||
| Capex | — | — | — | — | — | — | — | — | — | — | |||||
| Free cash flow | (2) | (7) | (18) | (26) | (5) | (4) | (8) | (9) | (9) | (2) | |||||
| Balance, $m | |||||||||||||||
| Balance, $m | Working capital | (6) | 19 | (1) | 7 | 2 | 3 | 3 | 1 | 2 | 2 | ||||
| Total debt | 2 | — | — | — | — | — | — | — | — | — | |||||
| Net debt | 2 | (22) | (3) | (9) | (3) | (4) | (7) | (2) | (3) | (3) | |||||
| Shareholders’ equity | (8) | 19 | (1) | 7 | 2 | 3 | 3 | 1 | 2 | 2 | |||||
| Returns, % | |||||||||||||||
| Returns, % | ROA | (3,011.37) | (109.61) | (161.44) | (385.54) | (84.72) | (103.57) | (65.75) | (238.69) | (515.35) | (103.84) | ||||
| ROIC | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| ROE | 47.48 | (220.23) | (229.86) | (839.94) | (112.48) | (128.43) | (105.76) | (529.44) | (928.45) | (157.75) | |||||
Negative figures in brackets.
Fiscal years to Dec 2025 · latest quarter Jun 2025
Charts ten years each
Avenue Therapeutics, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| CRIS Curis, Inc. | $1.1M | — (loss-making) | — (loss-making) | −65.98% (below 0%: shrinking) | n/m | −20.44% (below 0%: shrinking) | 100.00% | 0.00% | Compare |
| MNTRQ 9 Meters Biopharma, Inc. | $1.0M | — (loss-making) | — | −25.99% (below 0%: shrinking) | n/m | +0.01% (above 0%: growing) | 0.00% | 0.00% | Compare |
| ZVSA ZyVersa Therapeutics, Inc. | $970.0K | — (loss-making) | — | — | n/m | +54.91% (above 0%: growing) | 0.00% | 0.00% | Compare |
| LYRA Lyra Therapeutics, Inc. | $870.0K | — (loss-making) | — (loss-making) | −96.65% (below 0%: shrinking) | n/m | +45.44% (above 0%: growing) | 100.00% | (101,685.71%) | Compare |
| BTTX Better Therapeutics, Inc. | $850.0K | — (loss-making) | — | — | n/m | +20.43% (above 0%: growing) | 0.00% | 0.00% | Compare |
| SEELQ Seelos Therapeutics, Inc. | $700.0K | — (loss-making) | — (loss-making) | +11.90% (above 0%: growing) | n/m | +83.54% (above 0%: growing) | 100.00% | (834.84%) | Compare |
| ATXI Avenue Therapeutics, Inc. | $680.0K | — (loss-making) | — (loss-making) | — | n/m | −169.89% (below 0%: shrinking) | 100.00% | 0.00% | |
| SCNI Scinai Immunotherapeutics Ltd. Sponsored ADR | $640.0K | 0.0× | — (loss-making) | — | n/m | +51.13% (above 0%: growing) | (228.63%) | (504.50%) | Compare |
| BDRX Biodexa Pharmaceuticals PLC Unsponsored ADR | $440.0K | — (loss-making) | — | −32.27% (below 0%: shrinking) | +96.36% (above 0%: growing) | −0.17% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| Median of peers | $860.0K | — | — | −32.27% | — | +32.94% | 0.00% | 0.00% |
Avenue Therapeutics, Inc. (ATXI) key facts
- Avenue Therapeutics, Inc. (ATXI) is a Biotechnology company in the Healthcare sector.
- Avenue Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.4 million.
- As of October 15, 2026, ATXI traded at $0.43, a market capitalization of $680,000.00.
- Return on equity was −157.8% and debt-to-equity 0.00.
- Its Altman Z-score is −51.47 (distress zone) for fiscal 2025.